ImageneBio Inc
IMANASDAQHealthcare● Active
$5.63
$-0.02(-0.35%)
Market Cap$63501502
P/E Ratio—
52W High$18
52W Low$3.94
ImageneBio Inc (IMA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.95
Est. -$0.70 · -35.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
IMA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | -$0.98 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.70 | -$0.95 | -35.7% | — | — | — |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$1.45 | -$0.62 | +57.2% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$1.47 | -$2.91 | -98.0% | — | — | — |
| ▲ Q3 FY2025 | Jul 24, 2025 | -$0.14 | -$0.06 | +57.1% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.21 | -$0.18 | +14.3% | — | — | — |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.19 | -$0.18 | +5.3% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.27 | -$0.19 | +29.6% | — | — | — |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
-$0.98
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.95
EPS Est.
-$0.70
EPS Surpr.
-35.7%
Revenue
—
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.62
EPS Est.
-$1.45
EPS Surpr.
+57.2%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$2.91
EPS Est.
-$1.47
EPS Surpr.
-98.0%
Revenue
—
Q3 FY2025
Jul 24, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.14
EPS Surpr.
+57.1%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.21
EPS Surpr.
+14.3%
Revenue
—
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.19
EPS Surpr.
+5.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.19
EPS Est.
-$0.27
EPS Surpr.
+29.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2029 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q2 FY2029 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q1 FY2029 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q4 FY2028 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q3 FY2028 | $-0.57 | $-0.57 | $-0.57 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -35.7% | $6.08 | $5.91 | -2.80% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +57.2% | $5.92 | $6.07 | +2.53% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -98.0% | $8.61 | $8.55 | -0.70% |
| ▲ Q3 FY2025 | Jul 24, 2025 | +57.1% | $16.56 | $16.44 | -0.72% |
| ▲ Q2 FY2025 | May 8, 2025 | +14.3% | $13.08 | $12.96 | -0.92% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +5.3% | $16.20 | $17.16 | +5.93% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +29.6% | $20.64 | $20.28 | -1.74% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +12.9% | $19.56 | $19.56 | +0.00% |
Q2 FY2026-2.80%
Report Date
May 7, 2026
EPS Beat/Miss
-35.7%
Price Before
$6.08
Price After
$5.91
Q1 FY2026+2.53%
Report Date
Mar 10, 2026
EPS Beat/Miss
+57.2%
Price Before
$5.92
Price After
$6.07
Q4 FY2025-0.70%
Report Date
Nov 12, 2025
EPS Beat/Miss
-98.0%
Price Before
$8.61
Price After
$8.55
Q3 FY2025-0.72%
Report Date
Jul 24, 2025
EPS Beat/Miss
+57.1%
Price Before
$16.56
Price After
$16.44
Q2 FY2025-0.92%
Report Date
May 8, 2025
EPS Beat/Miss
+14.3%
Price Before
$13.08
Price After
$12.96
Q1 FY2025+5.93%
Report Date
Mar 6, 2025
EPS Beat/Miss
+5.3%
Price Before
$16.20
Price After
$17.16
Q4 FY2024-1.74%
Report Date
Nov 7, 2024
EPS Beat/Miss
+29.6%
Price Before
$20.64
Price After
$20.28
Q3 FY2024+0.00%
Report Date
Aug 8, 2024
EPS Beat/Miss
+12.9%
Price Before
$19.56
Price After
$19.56
Avg Beat Reaction+0.85%
Avg Miss Reaction-1.75%
Beat Rate6 / 8 quarters
Largest Move+5.93% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMA ends December
ImageneBio Inc (IMA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.95 — missing the analyst consensus of $-0.70 by -35.7%. The next IMA earnings date is expected around September 1, 2026.
Each quarter, investors track IMA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMA earnings · 5 questionsImageneBio Inc's next earnings report is expected around September 1, 2026. IMA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMA historically reports after market close (AMC).
IMA earnings datewhen is IMA earningsIMA next earnings datewhen does IMA report earningsIMA earnings calendar
▸ Source: FMP · ImageneBio Inc SEC filings · US GAAP · ImageneBio Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026